ACG posed several key questions and developed practical recommendations for practice providers. The recommendations were crafted through a focused literature search and supplemented by existing ...
Cologuard® CRC Screening Test Most Cost-Effective Test in Medically Underserved Alaska Native People
MADISON, Wis., April 28, 2021 /PRNewswire/ -- Exact Sciences (NASDAQ: EXAS) today announces study results published in Mayo Clinic Proceedings showing that Cologuard (mt-sDNA) is the most ...
New blood-based screening tests for colorectal cancer (CRC) offered fewer benefits at higher cost versus other screening options, a cost-effectiveness modeling study suggested. In a comparison against ...
Please provide your email address to receive an email when new articles are posted on . LAS VEGAS — Multimodal circulating tumor DNA blood-based colorectal cancer screening tests may have clinically ...
The FDA has approved the Cologuard Plus test, a next-generation, multitarget stool DNA test approved for patients at an average risk for colorectal cancer. The FDA’s approval was based on findings ...
Please provide your email address to receive an email when new articles are posted on . Newly available noninvasive colorectal cancer tests have opened the doors to an uptick in screening, especially ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood ...
WASHINGTON -- A blood-based test for the early detection of colorectal cancer (CRC) met its prespecified sensitivity and specificity endpoints, according to results from the PREEMPT CRC study. Using ...
Although considered a single class, fecal immunochemical tests (FITs) vary in their ability to detect advanced colorectal neoplasia (ACN) and should not be considered interchangeable, new research ...
Novel first-generation cell-free DNA blood (cf-bDNA) tests for colorectal cancer (CRC) cost more and are less effective than colonoscopy or stool tests, a new analysis suggests. Researchers estimated ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood ...
– As presented later this week at the ASCO GI conference, the large case-control validation study of nearly 1,000 samples highlights a head-to-head comparison with the test's first version, which is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results